RxDoctor Payments DataLook up a doctor →

Stephen Flitman, MD

Neurology · Phoenix, AZNPI 1023018223

Payments from drug & device makers

$4,369,120in general payments, 2019–2025

Across 1,372 payments — averaging $3184.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.3M
  • Biogen$912K
  • Genentech, Inc.$499K
  • UCB SA$248K
  • Eisai Inc.$222K
  • AbbVie$194K
  • plus $960K from 54 others
$771in research payments, 2019–2025

Across 4 payments — averaging $192.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$771

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer45$1,332,762
Biogen69$912,269
Genentech, Inc.59$499,048
UCB SA21$248,457
Eisai Inc.120$221,934
AbbVie(2 entities)228$194,068
Janssen Research & Development, LLC7$153,295
E.r. Squibb & Sons, L.L.C.12$149,527
Eli Lilly29$126,192
Amneal Pharmaceuticals LLC28$95,029
Osmotica Pharmaceutical Corp.8$69,794
Takeda Pharmaceuticals U.S.A., Inc.24$66,052
Alkermes, Inc.25$64,118
Novartis75$61,804
Biohaven Pharmaceutical Holding Company Ltd.20$54,861
SK Life Science, Inc.30$47,019
Otsuka Pharmaceutical Development & Commercialization, Inc.2$23,143
Bristol Myers Squibb18$12,704
Avanir Pharmaceuticals, Inc.1$11,900
Biohaven Pharmaceuticals, Inc.1$5,215
H. Lundbeck A S1$3,044
Sunovion Pharmaceuticals Inc.7$1,946
UCB, Inc.63$1,284
AstraZeneca(2 entities)16$875
Lilly USA, LLC33$750
Otsuka America Pharmaceutical, Inc.34$742
EMD Serono, Inc.18$708
Acadia Pharmaceuticals Inc34$674
Sanofi14$655
Lundbeck LLC28$640
Axsome Therapeutics, Inc.19$633
Neurocrine Biosciences, Inc.15$578
Teva Pharmaceuticals USA, Inc.23$535
Harmony Biosciences LLC14$519
Argenx US, Inc.19$492
Grifols USA, LLC16$476
Ipsen Biopharmaceuticals, Inc14$360
Jazz Pharmaceuticals Inc.11$344
Catalyst Pharmaceuticals, Inc.5$320
Neuropace, Inc.6$303
Mallinckrodt Hospital Products Inc.9$279
Acorda Therapeutics, Inc20$267
Amgen(2 entities)12$255
Merz Pharmaceuticals, LLC9$241
Abbott10$225
Neurelis, Inc.6$222
Vanda Pharmaceuticals Inc.5$210
Medtronic4$173
Inspire Medical Systems, Inc.2$134
Genentech USA, Inc.5$130
Promius Pharma LLC1$125
Kyowa Kirin, Inc.2$117
Idorsia Pharmaceuticals US Inc1$112
Corium, LLC6$108
Sumitomo Pharma America, Inc.7$107
ANI Pharmaceuticals, Inc.5$99
Johnson & Johnson6$96
MDD US Operations, LLC4$90
Upsher-smith Laboratories LLC5$83
Supernus Pharmaceuticals, Inc.5$79

How this compares

$4,369,120 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024
$110,682
Medicare patients
347
Services billed
2,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Phoenix

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →